Meeting
2023 ASCO Annual Meeting
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
Authors
Holger N. Lode
University Medicine Greifswald, Pediatric Hematology and Oncology, Greifswald, Germany
Holger N. Lode , Karoline Ehlert , Stephanie Huber , Nikolai Siebert , Sascha Troschke-Meurer , Maxi Zumpe , Hans Loibner , Ruth Lydia Ladenstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02743429
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10034)
DOI
10.1200/JCO.2023.41.16_suppl.10034
Abstract #
10034
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The role of autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy: Results of 2 consecutive studies in a single referral institution.
First Author: Jaume Mora
Poster
2022 ASCO Annual Meeting
Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
First Author: Thomas Cash
Poster
2022 ASCO Annual Meeting
Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.
First Author: Lucas Moreno
Poster
2022 ASCO Annual Meeting
Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.
First Author: Scott Moerdler